DNA-binding characteristics of aclarubicin as compared with daunorubicin and doxorubicin.
Satoshi Ando(University of Fukui), H Uchino, Tsuneyuki Nakamura(Fukuoka Children's Hospital and Medical Center for Infectious Diseases), Kazutaka Kamiya(Tokai University), Takanori Ueda(IBM (United States)), Hiroshi Tsutani, Teizo Yoshimura(Okayama University), M Uchida(Kyoto University)
PubMed
August 2, 1988
Cited by 5
Related Papers
Exploring the Multifaceted Nexus of Uric Acid and Health: A Review of Recent Studies on Diverse Diseases
|Biomolecules|2023|67
Midterm surgical results of total cavopulmonary connection: clinical advantages of the extracardiac conduit method
|Journal of Thoracic and Cardiovascular Surgery|2004|55
Overcoming imatinib resistance using Src inhibitor CGP76030, Abl inhibitor nilotinib and Abl/Lyn inhibitor INNO‐406 in newly established K562 variants with <i>BCR‐ABL</i> gene amplification
|International Journal of Cancer|2008|40
Meibomian Gland Dysfunction Clinical Practice Guidelines
|Japanese Journal of Ophthalmology|2023|35